News >

Mixed Findings Show Dose-Dense Therapy Noninferior to IP Treatment in Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Monday, Nov 06, 2017

Paul Sabbatini, MD

Paul Sabbatini, MD
Phase III findings of the ICON8 trial demonstrated that patients with ovarian cancer can safely undergo a 3-week dosing schedule of chemotherapy with paclitaxel versus a weekly dose-dense regimen, as neither approach was found to have a benefit in progression-free survival (PFS).1

State of the Science Summit™ on Treatment Options in Ovarian Cancer.

OncLive®: Please provide an overview of your presentation on IP therapy. 

Sabbatini: There has been a series of clinical trials in the last few years, which have really created some confusion about which modalities to offer people up front in ovarian cancer treatment. For example, the use of IP therapy or not, the use of bevacizumab (Avastin) or not, or the use of dose-dense therapy or not. More recently, additional trials have been done. A trial was reported at the 2017 ESMO Congress, which clarifies a lot of this for us going forward. 

What were the data presented at the 2017 ESMO Congress?

One question that has been relatively long-standing in upfront therapy for ovarian cancer is whether or not IP therapy should be used. There were some studies in the past that suggested that there were overall survival [OS] and PFS advantages for the use of IP treatment. Probably the best conducted study, GOG-252, just answers the question and says that IP therapy with either cisplatin or carboplatin does not offer any advantage over dose-dense therapy, and that we can be sure of.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication